MedPath

Merck & Co

Merck & Co logo
🇺🇸United States
Ownership
Public
Established
1891-01-01
Employees
72K
Market Cap
-
Website
http://www.merck.com
Introduction

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Clinical Trials

266

Active:264
Completed:2

Trial Phases

2 Phases

Phase 1:113
Phase 3:2

Drug Approvals

5

NMPA:5

Drug Approvals

Haemophilus b Conjugate Vaccine(Meningococcal Protein Conjugate)

Product Name
普泽欣
Approval Number
S20040078
Approval Date
Dec 27, 2004
NMPA

Pneumococcal Vaccine Polyvalent

Product Name
纽莫法
Approval Number
S20040047
Approval Date
Sep 14, 2004
NMPA

Hepatitis A Vaccine Purified Inactivated

Product Name
维康特
Approval Number
S20040041
Approval Date
Jul 23, 2004
NMPA

Hepatitis A Vaccine Purified Inactivated

Product Name
维康特
Approval Number
S20040040
Approval Date
Jul 23, 2004
NMPA

Indinavir Sulfate Capsules

Product Name
佳息患
Approval Number
H20030140
Approval Date
Mar 21, 2003
NMPA

Clinical Trials

Distribution across different clinical trial phases (115 trials with phase data)• Click on a phase to view related trials

Phase 1
113 (98.3%)
Phase 3
2 (1.7%)
No trials found

News

Sino Biopharm Acquires LaNova Medicines for $950M, Expanding Innovative Drug Pipeline

Sino Biopharm announced acquisition of remaining 95.09% stake in LaNova Medicines for up to $950 million, making it a wholly owned subsidiary.

FDA Approves First Year-Long Flea and Tick Injectable for Dogs

The FDA has approved BRAVECTO QUANTUM, the first and only parasiticide that protects dogs against fleas and ticks for an entire year with a single injection.

BioInvent's BI-1206 Shows Promising Phase 1 Results in Combination with Pembrolizumab for Solid Tumors

BioInvent's Phase 1 study of BI-1206 combined with pembrolizumab demonstrated encouraging clinical activity in heavily pre-treated solid tumor patients, with one complete response and one partial response among 36 evaluable patients.

Microbiotica Reveals Novel Mechanisms of Microbiome-Enhanced Immunotherapy Response with MB097

Microbiotica presented new preclinical data at the AACR annual meeting showing how MB097's bacterial strains enhance immune checkpoint inhibitor response through multiple mechanisms.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.